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Figure 2. Overall survival among Caucasian patients compared to African
American patients during the 24-month follow-up period (Log Rank¼0.25).
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variables between the two groups were assessed using stu-
dent t-test andWilcox log rank sum test; Chi-square test was
used for categorical variables. Kaplan Meier curves were
performed to assess survival and disease progression over
time.
Results: During this time 92 AA and 317 C patients under-
went ASCT. Median follow-up was 721 days in AA (IQR,
392e1103) versus (vs.) 735 days in C (IQR, 375e1124). The
mean age of AA at time of transplant was signiﬁcantly lower
than that of Caucasian pts (55.67 8 years vs. 57.74 8 years,
p¼ .032). Durie-Salmon stage distributionwas similar in two
groups with about 60% of patients in stage III at diagnosis.
Cytogenetic risk distribution was similar in two groups: (AA
vs. C) standard risk 82% vs. 86%; intermediate risk 16% vs.
10%, p ¼ 0.17; high risk 1.5% vs. 4%, p ¼ 0.34. Disease status at
the time of transplant was CR in 8% AA vs. 21% C (p¼0.03),
VGPR in 42% AA vs. 29% C (p¼0.66) and PR in 34% AA vs. 33%
C. The median time from diagnosis to ASCT in AA was
signiﬁcantly longer than that for C {288 days; IQR
(216.75e677.50) vs. 213 days; IQR (173.50e371.50), p¼
<0.001}. Induction therapy prior to transplant consisted of
novel agent (proteasome inhibitor and/or immunomodula-
tory agent) based regimens in all patients. Median number of
cycles of induction therapy was 5 (range 4-16) vs. 4 (range 3-
22) cycles in AA vs. C. Preparative regimen for ASCT was
Melphalan 140mg/m2 in 31% vs. 26% (AA vs. C) and
Melphalan 200mg/m2 in the rest. Rate of disease progression
after two-year median follow-up was higher in the AA pts
39% vs. 27%, OR 1.75 (1.08-2.85), p ¼ 0.02 (Figure 1). There
was no difference in the overall survival in two groups
after median follow-up of two years 86% vs. 90%, OR 1.47
(0.73e2.93) p ¼ 0.27 (Figure 2).
Conclusion: AA pts are diagnosed with MM at a younger age
as compared with C population. Time from diagnosis of MM
to referral to ASCT in the AA patients is longer than in the C.
In addition, the rate of disease progression post-ASCT is
higher in AA pts.159
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Introduction: Mantle cell lymphoma (MCL) is a rare B-cell
malignancy comprising 5-10% of all non-Hodgkin lymphoma
cases. Autologous hematopoietic stem cell transplant has
emerged as a viable therapy for many patients with MCL. An
important step in the harvesting of peripheral blood he-
matopoietic stem cells (HSC) is mobilizing CD34+ HSC to the
peripheral blood. The novel compound plerixafor is an
antagonist of CXCR4, and has been successful in mobilization
of HSC for autologous stem cell transplants for non-Hodgkin
lymphoma. Increased mobilization of HSC in peripheral
blood carries the risk of increased mobilization of lymphoma
cells. Since MCL expresses CXCR4, we sought to determine
whether administration of plerixafor can adversely affect
outcome in transplantation. We report survival results of
autologous peripheral blood stem cell transplants (ASCT) for
patients with MCL who were treated with and without
plerixafor for HSC mobilization prior to ASCT at Mayo Clinic.
Methods: The present study is a retrospective cohort study
of all adult patients who underwent ASCT for treatment of
MCL at Mayo Clinic from February 1993 to December 2013.
Patients were divided into two cohorts: (1) patients treated
with plerixafor for HSC mobilization prior to ASCT, and (2)
patients not treated with plerixafor prior to ASCT. The pri-
mary outcome was relapse of MCL. Overall survival from
diagnosis and overall survival from transplant were also
analyzed.
Patients: From 1993 to 2013, 169 consecutive patients un-
derwent ASCT; 55 patients received plerixafor for HSC
mobilization prior to ASCT, and 114 patients did not receive
plerixafor. The median ages at MCL diagnosis and ASCT for
the plerixafor cohort were 57.7 years and 58.4 years,
respectively, compared with 56.6 years and 58.1 years for the
non-plerixafor cohort.
Results: The average CD34+ HSC harvest with plerixafor was
5.4  106/kg compared to 4.9  106/kg without plerixafor (p
¼ 0.13). Median progression-free survival from ASCT was 3.4
years in the plerixafor cohort compared with 3.6 years in the
non-plerixafor cohort (p ¼ 0.69). Median overall survival
from ASCT was not reached in the plerixafor cohort
compared with 5.7 years in the non-plerixafor cohort (p ¼
0.95). Median overall survival from MCL diagnosis was 8.9
years in the plerixafor cohort compared with 7.6 years in the
non-plerixafor cohort (p ¼ 0.71).
Conclusions: ASCT for treatment of MCL performed at Mayo
Clinic resulted in no statistically signiﬁcant differences in
progression-free and overall survival between patients
receiving and patients not receiving plerixafor for CD34+HSC
mobilization prior to ASCT. The results of this study indicate
that HSC mobilization using plerixafor is not associated with
decreased progression-free or overall survival from ASCT in
MCL. There appears to be no clinically signiﬁcant mobiliza-
tion of lymphoma cells associated with plerixafor mobiliza-
tion of HSC.160
Engraftment Failure or Aplastic Anemia: A Case Report
JoAnn Liu 1, Angela Johns 2, Cristina Gasparetto 3. 1Medicine,
Duke University Medical Center, Durham, NC; 2 Division of
Cellular Therapy, Duke University Medical Center, Durham, NC;
3 Duke University Medical Center, Durham, NC
Secondary engraftment failure is deﬁned as neutrophils
increase to  0.5 x 10 ⁹/L and subsequently decrease to a
lower level until additional treatment to obtain
